| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:AS 2034178
CAS:1030846-42-4
Purity:98% by HPLC Remarks:AS 2034178 has been found to be a FFA1/GPR40 agonist and could probably be used against diabetes.
|
| Company Name: |
Hubei Yangxin Medical Technology Co., Ltd.
|
| Tel: |
15374522761 |
| Email: |
3003392093@qq.com |
| Products Intro: |
Product Name:Elacestrant Impurity 4
CAS:1030846-42-4
Purity:95% HPLC Package:10mg;25mg;50mg;100mg
|
| Company Name: |
Nantong QuanYi Biotechnology Co., Ltd
|
| Tel: |
0513-66337626 18051384581 |
| Email: |
sales@chemhifuture.com |
| Products Intro: |
Product Name:AS 2034178
CAS:1030846-42-4
Purity:98%+ HPLC Package:10mg，500mg，1g，2g，5g，10g，More
|
| Company Name: |
Chengdu Peter-like Biotechnology Co., Ltd.
|
| Tel: |
028-81700200 13308200041 |
| Email: |
2851167782@qq.com |
| Products Intro: |
Product Name:AS 2034178
CAS:1030846-42-4
Purity:>=98% 现货 Package:5mg10mg20mg50mg100mg500mg1g2g等应客户需求包装
|
|
| | AS2034178 Basic information |
| Product Name: | AS2034178 | | Synonyms: | AS2034178;2-Fluoro-4-[[[1,2,3,4-Tetrahydro-1-(2-phenoxyethyl)-5-quinolinyl]methyl]amino]benzenepropanoic acid;Benzenepropanoic acid, 2-fluoro-4-[[[1,2,3,4-tetrahydro-1-(2-phenoxyethyl)-5-quinolinyl]methyl]amino]- | | CAS: | 1030846-42-4 | | MF: | C27H29FN2O3 | | MW: | 448.53 | | EINECS: | | | Product Categories: | | | Mol File: | 1030846-42-4.mol |  |
| | AS2034178 Chemical Properties |
| Boiling point | 657.9±55.0 °C(Predicted) | | density | 1.240±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | <22.43mg/ml in DMSO; <8.97mg/ml in ethanol | | form | solid | | pka | 4.76±0.10(Predicted) | | color | White |
| | AS2034178 Usage And Synthesis |
| Uses | AS 2034178 is used in the synthetic preparation of quinolines and related compounds as GPR40 agonists, some of which are potentially useful in the treatment of diabetes. | | Biological Activity | as2034178 is a gpr40 agonist [1] with an hec50 value of 380 nm [2].gpr40 is a receptor of free fatty acid. it regulates glucose-dependent insulin secretion [1].as2034178 can improve glucose homeostasis and maintain or enhance islet beta cell functions [3]. as2034178 demonstrated highly and dose-dependently increase in intracellular ca2+ levels [1]. the maximum efficacy of the increase in ca2+ was nearly equal to that of an endogenous ligand of gpr40, namely linolenic acid. but the potency of as2034178 was much higher than that of linolenic acid. human gpr41-, gpr43-, gpr119-, and gpr120-overexpressing cho cells were developed to evaluate the increase of intracellular ca2+ concentration caused by as2034178. only gpr40-expressing cells showed increased intracellular ca2+. in pancreas b-cell–derived min6 cells, as2034178 dose-dependently and significantly induced insulin secretion only under high-glucose conditions (22.4 mm) [1].in ob/ob mice, chronic treatment with as2034178 significantly improved whole-body glucose metabolism, insulin, hba1c, and pancreatic insulin levels [2]. in normal mice, as2034178 at 0.3 to 10 mg/kg dose-dependently induced the suppression of plasma-glucose increases after oral administration with glucose, and the area decrease under the plasma glucose concentration-time curve was significant at doses over 1 mg/kg. after oral glucose administration, plasma insulin levels increased and at 5 minutes after glucose administration were dose-dependently and significantly increased at as2034178 dosages over 3 mg/kg [1]. | | references | [1]. tanaka h, yoshida s, oshima h, et al. chronic treatment with novel gpr40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion[j]. journal of pharmacology and experimental therapeutics, 2013, 346(3): 443-452.
[2]. defossa e, wagner m. recent developments in the discovery of ffa1 receptor agonists as novel oral treatment for type 2 diabetes mellitus[j]. bioorganic & medicinal chemistry letters, 2014, 24(14): 2991-3000.
[3]. milligan g, alvarez-curto e, watterson kr, et al. characterizing pharmacological ligands to study the long-chain fatty acid receptors gpr40/ffa1 and gpr120/ffa4[j]. british journal of pharmacology, 2015, 172(13): 3254-3265. |
| | AS2034178 Preparation Products And Raw materials |
|